251R-1
Factor XIIIa (EP3372) Rabbit Monoclonal Primary Antibody
Sign Into View Organizational & Contract Pricing
Select a Size
All Photos(1)
Select a Size
Change View
About This Item
UNSPSC Code:
12352203
NACRES:
NA.41
Recommended Products
biological source
rabbit
Quality Level
100
500
conjugate
unconjugated
antibody form
culture supernatant
antibody product type
primary antibodies
clone
EP3372, monoclonal
description
For In Vitro Diagnostic Use in Select Regions (See Chart)
form
buffered aqueous solution
species reactivity
human
packaging
vial of 0.1 mL concentrate (251R-14)
vial of 0.5 mL concentrate (251R-15)
bottle of 1.0 mL predilute (251R-17)
vial of 1.0 mL concentrate (251R-16)
bottle of 7.0 mL predilute (251R-18)
General description
Factor XIIIa is a plasma transglutaminase that is part of the blood coagulation cascade and plays a critical role in stabilizing fibrin networks at the site of an injury to produce a clot. Factor XIIIa is expressed in platelets, megakaryocytes, fibroblast-like cells in the placenta, uterus, and prostate, monocytes and macrophages, and dermal dendritic cells. Anti-Factor XIIIa immunohistochemistry is used to identify fibrohistiocytic neoplasms such as dermatofibroma.
Factor XIIIa is a blood proenzyme that has been identified in platelets, megakaryocyte, and fibroblast-like mesenchymal or histiocytic cells present in the placenta, uterus, and prostate; it is also present in monocytes and macrophages and dermal dendritic cells. Anti- Factor XIIIa has been found to be useful in differentiating between dermatofibroma (90% (+)), dermatofibrosarcoma protuberans (25%(+)) and desmoplastic malignant melanoma (0%(+)). Factor XIIIa positivity is also seen in capillary hemagioblastoma (100%(+)), hemangioendothelioma (100%(+)), hemangiopericytoma (100%(+)), xanthogranuloma (100%(+)), xanthoma (100(+)), hepatocellular carcinoma (93%(+)), glomus tumor (80%(+)), and meningioma (80 % (+)).
Factor XIIIa is a blood proenzyme that has been identified in platelets, megakaryocyte, and fibroblast-like mesenchymal or histiocytic cells present in the placenta, uterus, and prostate; it is also present in monocytes and macrophages and dermal dendritic cells. Anti- Factor XIIIa has been found to be useful in differentiating between dermatofibroma (90% (+)), dermatofibrosarcoma protuberans (25%(+)) and desmoplastic malignant melanoma (0%(+)). Factor XIIIa positivity is also seen in capillary hemagioblastoma (100%(+)), hemangioendothelioma (100%(+)), hemangiopericytoma (100%(+)), xanthogranuloma (100%(+)), xanthoma (100(+)), hepatocellular carcinoma (93%(+)), glomus tumor (80%(+)), and meningioma (80 % (+)).
Quality
 IVD |  IVD |  IVD |  RUO |
Linkage
Factor XIIIa Positive Control Slides , Product No. 251S, are available for immunohistochemistry (formalin-fixed, paraffin-embedded sections).
Physical form
Solution in Tris Buffer, pH 7.3-7.7, with 1% BSA and <0.1% Sodium Azide
Preparation Note
Download the IFU specific to your product lot and formatNote: This requires a keycode which can be found on your packaging or product label.
Other Notes
For Technical Service please contact: 800-665-7284 or email: service@cellmarque.com
Legal Information
Cell Marque is a registered trademark of Merck KGaA, Darmstadt, Germany
Not finding the right product?
Try our Product Selector Tool.
Choose from one of the most recent versions:
Certificates of Analysis (COA)
Lot/Batch Number
Don't see the Right Version?
If you require a particular version, you can look up a specific certificate by the Lot or Batch number.
Already Own This Product?
Find documentation for the products that you have recently purchased in the Document Library.
Z Nemes
Human pathology, 23(7), 805-810 (1992-07-01)
Seven cases of capillary hemangioblastoma from the cerebellum and spinal cord were studied by immunohistochemical methods to determine the origin of the stromal cells. A subpopulation of factor XIIIa-positive tumor cells was a constant feature in hemangioblastomas. These stellate or
P Abenoza et al.
The American Journal of dermatopathology, 15(5), 429-434 (1993-10-01)
To assess the use of anti-CD34 and anti-factor-XIIIa antibodies for the differential diagnosis of dermatofibroma (DF) and dermatofibrosarcoma protuberans (DFSP), we stained 40 DFs and 13 DFSPs. A significant population of dendritic and spindle cells was reactive with anti-factor-XIIIa in
E J Glusac et al.
The American journal of surgical pathology, 18(6), 583-590 (1994-06-01)
Epithelioid cell histiocytoma is a recently recognized lesion that is considered to be a variant of cutaneous fibrous histiocytoma (dermatofibroma). Ten cases are presented, including their light microscopic, immunohistochemical, and ultrastructural features. Eight of the cases are similar to those
Louis P Dehner
The American journal of surgical pathology, 27(5), 579-593 (2003-04-30)
Juvenile xanthogranulomas (JXG) is a histiocytic disorder, primarily but not exclusively seen throughout the first two decades of life and principally as a solitary cutaneous lesion. This study is a retrospective clinical and pathologic review of 174 cases documenting the
A J Demetris et al.
The American journal of surgical pathology, 21(3), 263-270 (1997-03-01)
Epithelioid hemangioendothelioma (EHE) is best considered a vascular neoplasm of intermediate malignancy. Although usually progressive, the clinical course is highly unpredictable. The present communication describes a case of extensive recurrent hepatic EHE, limited to the liver allograft and initially manifest
Articles
IHC antibodies enhance dermatopathology beyond H&E stained slides, improving techniques and applications for dermatological research.
Our team of scientists has experience in all areas of research including Life Science, Material Science, Chemical Synthesis, Chromatography, Analytical and many others.
Contact Technical Service